|NASDAQ: CERE||Healthcare / Biotechnology / USA|
|23.43||0||0.00||Vol 422.41K||1Y Perf -31.21%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||41.25||Analyst Rating||Moderate Buy 1.62|
|Potential %||76.06||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||16.53||Earnings Rating||—|
|Market Cap||3.67B||Earnings Date||9th May 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th May 2023|
|Estimated EPS Next Report||-0.67|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||927.26K|
|Avg. Monthly Volume||745.80K|
|Avg. Quarterly Volume||606.28K|
Cerevel Therapeutics Holdings Inc. (NASDAQ: CERE) stock closed at 23.43 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 422.41K shares and market capitalization of 3.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 104 people. Cerevel Therapeutics Holdings Inc. CEO is N. Anthony Coles.
The one-year performance of Cerevel Therapeutics Holdings Inc. stock is -31.21%, while year-to-date (YTD) performance is -25.71%. CERE stock has a five-year performance of %. Its 52-week range is between 19.86 and 41.46, which gives CERE stock a 52-week price range ratio of 16.53%
Cerevel Therapeutics Holdings Inc. currently has a PE ratio of -14.40, a price-to-book (PB) ratio of 7.96, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.05%, a ROC of -39.39% and a ROE of -55.93%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cerevel Therapeutics Holdings Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. Cerevel Therapeutics Holdings Inc.’s next earnings report date is 09th May 2023.
The consensus rating of Wall Street analysts for Cerevel Therapeutics Holdings Inc. is Moderate Buy (1.62), with a target price of $41.25, which is +76.06% compared to the current price. The earnings rating for Cerevel Therapeutics Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cerevel Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cerevel Therapeutics Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 53.60, ATR14 : 1.39, CCI20 : -101.70, Chaikin Money Flow : 0.03, MACD : -1.77, Money Flow Index : 34.57, ROC : -11.92, RSI : 34.49, STOCH (14,3) : 15.53, STOCH RSI : 0.80, UO : 44.69, Williams %R : -84.47), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cerevel Therapeutics Holdings Inc. in the last 12-months were: Abraham Ceesay (Option Excercise at a value of $1 265 058), Abraham Ceesay (Sold 96 056 shares of value $3 255 048 ), Deval L. Patrick (Option Excercise at a value of $602 037), Deval L. Patrick (Sold 47 705 shares of value $1 468 421 ), Gabrielle Sulzberger (Option Excercise at a value of $0), John Renger (Option Excercise at a value of $1 219 073), John Renger (Sold 241 105 shares of value $8 200 133 ), N. Anthony Coles (Option Excercise at a value of $700 000), N. Anthony Coles (Sold 200 000 shares of value $5 842 516 ), Scott Akamine (Option Excercise at a value of $131 700), Scott Akamine (Sold 10 000 shares of value $400 001 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Strong Buy||Strong Buy|
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
CEO: N. Anthony Coles
Telephone: +1 844 304-2048
Address: 222 Jacobs Street, Cambridge 02141, MA, US
Number of employees: 104
Thu, 09 Mar 2023 11:05 GMT Cerevel Therapeutics Holdings (CERE) Gets a Hold from Mizuho Securities- TipRanks. All rights reserved.
Wed, 15 Feb 2023 12:15 GMT Cerevel Therapeutics Holdings (CERE) Receives a Hold from Mizuho Securities- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.